Abatacept clinical trials
Also written Orencia, Belatacept, Nulojix and BMS-188667.
How each study uses Abatacept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Abatacept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Dec 2005 · ORENCIA · BLA 125118 (FDA, Drugs@FDA)
- European Union
- 21 May 2007 · Orencia · EMEA/H/C/000701 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
218 studies that test it; most in 2013 (23)
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1997 | 1 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 6 |
| 2006 | 6 |
| 2007 | 14 |
| 2008 | 14 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 23 |
| 2014 | 16 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 12 |
| 2020 | 10 |
| 2021 | 13 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 68 · Other 150
Bristol-Myers Squibb (65) · National Institute of Allergy and Infectious Diseases (NIAID) (16) · Emory University (5) · NYU Langone Health (5) · University of California, Los Angeles (5) · Duke University (4) · Massachusetts General Hospital (4) · Columbia University (4)
Often tested with
Tested in the same studies.
Methotrexate (8) · Tocilizumab (8) · Adalimumab (7) · Certolizumab Pegol (6) · Sirolimus (6) · Etanercept (5) · Tofacitinib (5) · Infliximab (5)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10, 2 in phase 3
Studies that test Abatacept, phase 3 first.
- Nov 2026Efficacy of a Sequential Treatment Strategy in Rheumatoid ArthritisPhase 3 · University Hospital, Montpellier
- Jun 2027Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesPhase 2/3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Dec 2026Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorPhase 2 · St. Petersburg State Pavlov Medical University
- Jan 2027Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHDPhase 2 · NYU Langone Health
- Mar 2027Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant TransplantPhase 2 · Emory University
- Mar 2027Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesPhase 2 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Mar 2027Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaPhase 1 · National Cancer Institute (NCI)
- May 2027Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease ProphylaxisPhase 2 · Boston Children's Hospital
- Jun 2027Treatment of Antibody-Mediated Rejection (ABMR) With CarBelPhase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Jul 2027Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
Studies
Open first, then newest update. How each study uses Abatacept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 218
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT07616154Written as Abatacept
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT07388563Written as abatacept
- HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCTRecruitingEarly Phase 1Duke UniversityNCT06731504Written as Abatacept
- Advancing Transplantation Outcomes in ChildrenRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06055608Written as Belatacept
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06918990Written as Belatacept
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingPhase 3Duke UniversityNCT06654882Written as Abatacept
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT07599176Written as Abatacept
- Belatacept in Heart TransplantationRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06478017Written as Belatacept
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsRecruitingPhase 3Bristol-Myers SquibbNCT04877288Written as Belatacept
- Abatacept in Immune Checkpoint Inhibitor MyocarditisRecruitingPhase 3Massachusetts General HospitalNCT05335928Written as Abatacept plus
- Abatacept for the Treatment of Giant Cell ArteritisRecruitingPhase 3University of PennsylvaniaNCT04474847Written as Abatacept
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung DiseaseRecruitingPhase 2Children's Hospital Medical Center, CincinnatiNCT04925375Written as Abatacept
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Abatacept
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Abatacept
- Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>RecruitingPhase 4University Hospital, RouenNCT06291077Written as Belatacept
- Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingPhase 1/2Northwell HealthNCT05289167Written as Abatacept
- Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease ProphylaxisRecruitingPhase 2Boston Children's HospitalNCT04380740Written as Abatacept
- Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss TherapyRecruitingPhase 2Linda CendalesNCT02310867Written as Belatacept
- Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05917522Written as Abatacept
- Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingPhase 2/3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07366801Written as Abatacept
See all 218 studies that test Abatacept →
Given beside what is tested · 12 — Abatacept is usual care or a partner of the new treatment
- Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationRecruitingPhase 1Washington University School of MedicineNCT06008808Written as Abatacept
- Tolerance by Engaging Antigen During Cellular HomeostasisCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03504241Written as belatacept
- Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04066114Written as belatacept
- A Study of TCD601 in de Novo Renal Transplant RecipientsCompletedPhase 2ITB-Med LLCNCT05669001Written as belatacept
- Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT06145282Written as Abatacept
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney TransplantCompletedPhase 2AmgenNCT04046549Written as Belatacept
- A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)CompletedPhase 4Astellas Pharma Korea, Inc.NCT03737708Written as abatacept
- Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis PatientsCompletedNot applicableUniversity Hospital, MontpellierNCT02547493Written as Abatacept
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)Status unknownPhase 4University of CincinnatiNCT04849533Written as Belatacept
- Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisCompletedPhase 4Bristol-Myers SquibbNCT02557100Written as Abatacept
- Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)CompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00094380Written as CTLA4-IgG4m (RG2077)
- Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)CompletedPhase 3Novartis PharmaceuticalsNCT01350804Written as Abatacept
As the comparator · 6 — what is tested is compared with Abatacept
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsCompletedPhase 3AbbVieNCT03086343Written as Abatacept
- Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory MyopathyCompletedPhase 3Bristol-Myers SquibbNCT02971683Written as Abatacept subcutaneous
- Immune Modulators for Treating COVID-19CompletedPhase 3Daniel BenjaminNCT04593940Written as Abatacept
- TOward the Lowest Effective DOse of Abatacept or TocilizumabCompletedPhase 4Assistance Publique - Hôpitaux de ParisNCT01557374Written as Tocilizumab, Abatacept
- Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy SubjectsCompletedPhase 1Momenta Pharmaceuticals, Inc.NCT02923583Written as US-Sourced Orencia®
- Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsCompletedPhase 2/3Bristol-Myers SquibbNCT01001832Written as Intravenous (IV) abatacept
Codes
What other systems call Abatacept · ClinicalTrials.gg INT006617
- MeSH (NLM) D000069594AbataceptConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7D0YB67S97ABATACEPTConfirmed FDA, NLM, Wikidata
- RxNorm 614391Confirmed FDA, Wikidata
- Wikidata Q2697833abataceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28898AbataceptOne source FDA
- DrugBank DB01281One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069594 | Abatacept | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7D0YB67S97 | ABATACEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 614391 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2697833 | abatacept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28898 | Abatacept | One source FDA |
| DrugBank | DB01281 | — | One source Wikidata |
Also registered as belatacept (UNII E3B2GI648A · RxNorm 1112973).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.